BioInvent International AB (LTS:0H22) Interest Expense : kr0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to . Start your Free Trial

What is BioInvent International AB Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. BioInvent International AB's interest expense for the three months ended in Dec. 2024 was kr 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was kr0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. BioInvent International AB's Operating Income for the three months ended in Dec. 2024 was kr -125.87 Mil. BioInvent International AB's Interest Expense for the three months ended in Dec. 2024 was kr 0.00 Mil. GuruFocus does not calculate BioInvent International AB's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

BioInvent International AB Interest Expense Historical Data

The historical data trend for BioInvent International AB's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioInvent International AB Interest Expense Chart

BioInvent International AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

-0.34

-0.52

-0.65

-0.64

BioInvent International AB Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

BioInvent International AB Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

BioInvent International AB (LTS:0H22) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

BioInvent International AB's Interest Expense for the three months ended in Dec. 2024 was kr0.00 Mil. Its Operating Income for the three months ended in Dec. 2024 was kr-125.87 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2024 was kr8.22 Mil.

BioInvent International AB's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

GuruFocus does not calculate BioInvent International AB's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. BioInvent International AB has enough cash to cover all of its debt. Its financial situation is stable.

BioInvent International AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioInvent International AB (LTS:0H22) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

BINV:Sweden BIX0:Germany

Address

Ideongatan 1, Lund, SWE, SE-223 70

Website

https://www.bioinvent.com

BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's own clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.

BioInvent International AB Headlines

No Headlines